- Home
- BZFD vs BMEA Comparison
BZFD vs BMEA Comparison
Compare BZFD & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZFD
- BMEA
- Stock Information
- Founded
- BZFD 2006
- BMEA 2017
- Country
- BZFD United States
- BMEA United States
- Employees
- BZFD N/A
- BMEA N/A
- Industry
- BZFD Movies/Entertainment
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- BZFD Consumer Discretionary
- BMEA Health Care
- Exchange
- BZFD Nasdaq
- BMEA Nasdaq
- Market Cap
- BZFD 65.1M
- BMEA 65.8M
- IPO Year
- BZFD N/A
- BMEA 2021
- Fundamental
- Price
- BZFD $1.73
- BMEA $1.69
- Analyst Decision
- BZFD
- BMEA Buy
- Analyst Count
- BZFD 0
- BMEA 12
- Target Price
- BZFD N/A
- BMEA $28.45
- AVG Volume (30 Days)
- BZFD 315.4K
- BMEA 804.4K
- Earning Date
- BZFD 05-12-2025
- BMEA 05-01-2025
- Dividend Yield
- BZFD N/A
- BMEA N/A
- EPS Growth
- BZFD N/A
- BMEA N/A
- EPS
- BZFD N/A
- BMEA N/A
- Revenue
- BZFD $189,887,000.00
- BMEA N/A
- Revenue This Year
- BZFD $89.62
- BMEA N/A
- Revenue Next Year
- BZFD $4.50
- BMEA N/A
- P/E Ratio
- BZFD N/A
- BMEA N/A
- Revenue Growth
- BZFD N/A
- BMEA N/A
- 52 Week Low
- BZFD $1.26
- BMEA $1.53
- 52 Week High
- BZFD $5.68
- BMEA $13.43
- Technical
- Relative Strength Index (RSI)
- BZFD 37.09
- BMEA 35.25
- Support Level
- BZFD $1.65
- BMEA $1.54
- Resistance Level
- BZFD $1.79
- BMEA $2.21
- Average True Range (ATR)
- BZFD 0.15
- BMEA 0.25
- MACD
- BZFD -0.02
- BMEA -0.00
- Stochastic Oscillator
- BZFD 15.25
- BMEA 21.05
About BZFD BuzzFeed Inc.
BuzzFeed Inc is a tech-powered, diversified media company that reaches hundreds of millions globally through its cross-platform news and entertainment network. The company produces articles, lists, quizzes, videos, and original series; lifestyle content through brands including Tasty, social food network; original reporting and investigative journalism through BuzzFeed News and HuffPost; an industry- affiliate business, strategic partnerships, licensing and product development through BuzzFeed Commerce; and original productions across broadcast, cable, SVOD, film and digital platforms for BuzzFeed Studios.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.